Other biologics targeting type 2 immunity, such as anti-IL-4Rα (targeting both IL-4 and IL-13, dupilumab) (56) or anti-TSLP (tezepelumab) (57), are to date in phase II or III trials in type-2- and non-type-2-immunity-driven asthma (Figure 2). This evidence concerns the gene IL13 and asthma.